K Takano1, M Kinoshita2, H Arita3, Y Okita4, Y Chiba5, N Kagawa3, Y Fujimoto6, H Kishima3, Y Kanemura7, M Nonaka8, S Nakajima4, E Shimosegawa9, J Hatazawa9, N Hashimoto3, T Yoshimine3. 1. From the Department of Neurosurgery (K.T., M.K.), Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan Departments of Neurosurgery (K.T., M.K., H.A., Y.C., N.K., H.K., N.H., T.Y.). 2. From the Department of Neurosurgery (K.T., M.K.), Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan Departments of Neurosurgery (K.T., M.K., H.A., Y.C., N.K., H.K., N.H., T.Y.) m-kinoshita@nsurg.med.osaka-u.ac.jp. 3. Departments of Neurosurgery (K.T., M.K., H.A., Y.C., N.K., H.K., N.H., T.Y.). 4. Department of Neurosurgery (Y.O., Y.K., M.N., S.N.). 5. Departments of Neurosurgery (K.T., M.K., H.A., Y.C., N.K., H.K., N.H., T.Y.) Department of Neurosurgery (Y.C.), Kansai Rosai Hospital, Itami, Japan. 6. Department of Neurosurgery (Y.F.), Osaka Neurological Institute, Osaka, Japan. 7. Department of Neurosurgery (Y.O., Y.K., M.N., S.N.) Division of Regenerative Medicine (Y.K.), Institute for Clinical Research, Osaka National Hospital, National Hospital Organization, Osaka, Japan. 8. Department of Neurosurgery (Y.O., Y.K., M.N., S.N.) Department of Neurosurgery (M.N.), Kansai Medical University, Osaka, Japan. 9. Nuclear Medicine and Tracer Kinetics (E.S., J.H.), Osaka University Graduate School of Medicine, Osaka, Japan.
Abstract
BACKGROUND AND PURPOSE: Noninvasive radiologic evaluation of glioma can facilitate correct diagnosis and detection of malignant transformation. Although positron-emission tomography is considered valuable in the care of patients with gliomas, (18)F-fluorodeoxyglucose and (11)C-methionine have reportedly shown ambiguous results in terms of grading and prognostication. The present study compared the diagnostic and prognostic capabilities of diffusion tensor imaging, FDG, and (11)C-methionine PET in nonenhancing gliomas. MATERIALS AND METHODS: Thirty-five consecutive newly diagnosed, histologically confirmed nonenhancing gliomas that underwent both FDG and (11)C-methionine PET were retrospectively investigated (23 grade II and 12 grade III gliomas). Apparent diffusion coefficient, fractional anisotropy, and tumor-to-normal tissue ratios of both FDG and (11)C-methionine PET were compared between grade II and III gliomas. Prognostic values of these parameters were also tested by using progression-free survival. RESULTS: Grade III gliomas showed significantly higher average tumor-to-normal tissue and maximum tumor2-to-normal tissue than grade II gliomas in (11)C-methionine (P = .013, P = .0017, respectively), but not in FDG-PET imaging. There was no significant difference in average ADC, minimum ADC, average fractional anisotropy, and maximum fractional anisotropy. (11)C-methionine PET maximum tumor-to-normal tissue ratio of 2.0 was most suitable for detecting grade III gliomas among nonenhancing gliomas (sensitivity, 83.3%; specificity, 73.9%). Among patients not receiving any adjuvant therapy, median progression-free survival was 64.2 ± 7.2 months in patients with maximum tumor-to-normal tissue ratio of <2.0 for (11)C-methionine PET and 18.6 ± 6.9 months in patients with maximum tumor-to-normal tissue ratio of >2.0 (P = .0044). CONCLUSIONS: (11)C-methionine PET holds promise for World Health Organization grading and could offer a prognostic imaging biomarker for nonenhancing gliomas.
BACKGROUND AND PURPOSE: Noninvasive radiologic evaluation of glioma can facilitate correct diagnosis and detection of malignant transformation. Although positron-emission tomography is considered valuable in the care of patients with gliomas, (18)F-fluorodeoxyglucose and (11)C-methionine have reportedly shown ambiguous results in terms of grading and prognostication. The present study compared the diagnostic and prognostic capabilities of diffusion tensor imaging, FDG, and (11)C-methionine PET in nonenhancing gliomas. MATERIALS AND METHODS: Thirty-five consecutive newly diagnosed, histologically confirmed nonenhancing gliomas that underwent both FDG and (11)C-methionine PET were retrospectively investigated (23 grade II and 12 grade III gliomas). Apparent diffusion coefficient, fractional anisotropy, and tumor-to-normal tissue ratios of both FDG and (11)C-methionine PET were compared between grade II and III gliomas. Prognostic values of these parameters were also tested by using progression-free survival. RESULTS: Grade III gliomas showed significantly higher average tumor-to-normal tissue and maximum tumor2-to-normal tissue than grade II gliomas in (11)C-methionine (P = .013, P = .0017, respectively), but not in FDG-PET imaging. There was no significant difference in average ADC, minimum ADC, average fractional anisotropy, and maximum fractional anisotropy. (11)C-methionine PET maximum tumor-to-normal tissue ratio of 2.0 was most suitable for detecting grade III gliomas among nonenhancing gliomas (sensitivity, 83.3%; specificity, 73.9%). Among patients not receiving any adjuvant therapy, median progression-free survival was 64.2 ± 7.2 months in patients with maximum tumor-to-normal tissue ratio of <2.0 for (11)C-methionine PET and 18.6 ± 6.9 months in patients with maximum tumor-to-normal tissue ratio of >2.0 (P = .0044). CONCLUSIONS: (11)C-methionine PET holds promise for World Health Organization grading and could offer a prognostic imaging biomarker for nonenhancing gliomas.
Authors: Nina Poetsch; Adelheid Woehrer; Johanna Gesperger; Julia Furtner; Alexander R Haug; Dorothee Wilhelm; Georg Widhalm; Georgios Karanikas; Michael Weber; Ivo Rausch; Markus Mitterhauser; Wolfgang Wadsak; Marcus Hacker; Matthias Preusser; Tatjana Traub-Weidinger Journal: Neuro Oncol Date: 2018-02-19 Impact factor: 12.300
Authors: Cornelius Deuschl; Sophia Goericke; Johannes Grueneisen; Lino Morris Sawicki; Juliane Goebel; Nicolai El Hindy; Karsten Wrede; Ina Binse; Thorsten Poeppel; Harald Quick; Michael Forsting; Joerg Hense; Lale Umutlu; Marc Schlamann Journal: PLoS One Date: 2016-12-01 Impact factor: 3.240
Authors: Yae Won Park; Yoon Seong Choi; Sung Soo Ahn; Jong Hee Chang; Se Hoon Kim; Seung Koo Lee Journal: Korean J Radiol Date: 2019-09 Impact factor: 3.500